UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 380

Sortiert nach

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Cancer cell, 2021-08, Vol.39 (8), p.1091-1098.e2

2021

Volltextzugriff (PDF)

Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer

The Prostate, 2013-06, Vol.73 (8), p.813-826

2013

Volltextzugriff (PDF)

Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration

Diabetes (New York, N.Y.), 2021-06, Vol.70 (6), p.1303-1316

2021

Volltextzugriff (PDF)

Prostate Cancer Prevention Trial Risk Calculator 2.0 for the Prediction of Low- vs High-grade Prostate Cancer

Urology (Ridgewood, N.J.), 2014-06, Vol.83 (6), p.1362-1368

2014

Volltextzugriff (PDF)

A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts

European urology, 2018-08, Vol.74 (2), p.197-203

2018

Volltextzugriff (PDF)

Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort

European urology, 2022-08, Vol.82 (2), p.163-169

2022

Volltextzugriff (PDF)

Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review

Cancer epidemiology, biomarkers & prevention, 2020-12, Vol.29 (12), p.2454-2462

2020

Volltextzugriff (PDF)

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial

PloS one, 2015-05, Vol.10 (5), p.e0126672-e0126672

2015

Volltextzugriff (PDF)

Comparison of rectal swab, glove tip, and participant-collected stool techniques for gut microbiome sampling

BMC microbiology, 2021-01, Vol.21 (1), p.26-26, Article 26

2021

Volltextzugriff (PDF)

Effects of vortioxetine on hippocampal-related cognitive impairment induced in rats by androgen deprivation as a model of prostate cancer treatment

Translational psychiatry, 2023-10, Vol.13 (1), p.307-307, Article 307

2023

Volltextzugriff (PDF)

The glycosylation landscape of prostate cancer tissues and biofluids

Advances in cancer research, 2024-01, Vol.161, p.1

2024

Volltextzugriff (PDF)

A Scaled Proteomic Discovery Study for Prostate Cancer Diagnostic Markers Using ProteographTM and Trapped Ion Mobility Mass Spectrometry

International journal of molecular sciences, 2024-07, Vol.25 (15), p.8010

2024

Volltextzugriff (PDF)

A genome‐wide association study of prostate cancer in Latinos

International journal of cancer, 2020-04, Vol.146 (7), p.1819-1826

2020

Volltextzugriff (PDF)

Identification of viral infections in the prostate and evaluation of their association with cancer

BMC cancer, 2010-06, Vol.10 (1), p.326-326, Article 326

2010

Volltextzugriff (PDF)

Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms

Journal of proteome research, 2023-03, Vol.22 (3), p.942-950

2023

Volltextzugriff (PDF)

The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial

PloS one, 2018-10, Vol.13 (10), p.e0204823

2018

Volltextzugriff (PDF)

Accommodating heterogeneous missing data patterns for prostate cancer risk prediction

BMC medical research methodology, 2022-07, Vol.22 (1), p.200-200, Article 200

2022

Volltextzugriff (PDF)

Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer

The Journal of urology, 2016-08, Vol.196 (2), p.355-360

2016

Volltextzugriff (PDF)

Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3

The Journal of urology, 2008-10, Vol.180 (4), p.1303-1308

2008

Volltextzugriff (PDF)

Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making

JAMA : the journal of the American Medical Association, 2014-09, Vol.312 (10), p.995

2014

Volltextzugriff (PDF)

Incorporation of Detailed Family History from the Swedish Family Cancer Database into the PCPT Risk Calculator

The Journal of urology, 2015-02, Vol.193 (2), p.460-465

2015

Volltextzugriff (PDF)

MBDDiff: an R package designed specifically for processing MBDcap-seq datasets

BMC genomics, 2016-08, Vol.17 Suppl 4 (1), p.432-432, Article 432

2016

Volltextzugriff (PDF)

Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial

The Prostate, 2016-09, Vol.76 (12), p.1120-1129

2016

Volltextzugriff (PDF)

Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening

The Journal of urology, 2015-07, Vol.194 (1), p.46-51

2015

Volltextzugriff (PDF)

A copy number gain on 18q present in primary prostate tumors is associated with metastatic outcome

Urologic oncology, 2020-12, Vol.38 (12), p.932.e1-932.e7

2020

Volltextzugriff (PDF)

1 – 25 von 380

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(331)
Mit Volltextzugriff
(299)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer

Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer

Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration

Prostate Cancer Prevention Trial Risk Calculator 2.0 for the Prediction of Low- vs High-grade Prostate Cancer

A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts

Defining the Impact of Family History on Detection of High-grade Prostate Cancer in a Large Multi-institutional Cohort

Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial

Comparison of rectal swab, glove tip, and participant-collected stool techniques for gut microbiome sampling

Effects of vortioxetine on hippocampal-related cognitive impairment induced in rats by androgen deprivation as a model of prostate cancer treatment

The glycosylation landscape of prostate cancer tissues and biofluids

A Scaled Proteomic Discovery Study for Prostate Cancer Diagnostic Markers Using ProteographTM and Trapped Ion Mobility Mass Spectrometry

A genome‐wide association study of prostate cancer in Latinos

Identification of viral infections in the prostate and evaluation of their association with cancer

Targeted Mass Spectrometry Assays for Specific Quantification of Urinary proPSA Isoforms

The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial

Accommodating heterogeneous missing data patterns for prostate cancer risk prediction

Serial Percent Free Prostate Specific Antigen in Combination with Prostate Specific Antigen for Population Based Early Detection of Prostate Cancer

Predicting Prostate Cancer Risk Through Incorporation of Prostate Cancer Gene 3

Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making

Incorporation of Detailed Family History from the Swedish Family Cancer Database into the PCPT Risk Calculator

MBDDiff: an R package designed specifically for processing MBDcap-seq datasets

Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial

Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening

A copy number gain on 18q present in primary prostate tumors is associated with metastatic outcome

Aktive Filter

Suchergebnisse filtern